Open AccessRole of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era
Author(s) -
Fatma Sert,
Serra Kamer,
Güray Saydam,
Yavuz Anacak
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_3_17
Subject(s) - rituximab , medicine , diffuse large b cell lymphoma , lymphoma , stage (stratigraphy) , radiation therapy , chemotherapy , chop , oncology , radiology , gastroenterology , paleontology , biology
The most common subtype of aggressive non-Hodgkin Lymphomas is diffuse large B-cell lymphoma (DLBCL). Mediastinal DLBCL is a distinct entity with unique clinical, pathologic, and genetic features and accepted as a subtype of DLBCL. The aim of this study is to evaluate the patients treated with consolidative radiotherapy (RT) after rituximab-containing chemotherapy for mediastinal DLBCL regarding treatment outcomes and relapse patterns.